Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Granulocyte colony-stimulating factor added to induction chemotherapy for non-M3 acute myeloid leukemia
IRCT20211219053451N1Phase 2Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Jan 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of granulocyte colony-stimulating factor in acute myeloid leukemia (AML) (2 arms), sponsored by Mashhad University of Medical Sciences. Primary endpoints: Disease extinction and One-year survival. Started Jan 2022; status: completed.
02
Drugs
granulocyte colony-stimulating factor
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on IRCT20211219053451N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20211219053451N1.